The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms

In 2005, the description of the JAK2V617F mutation for the first time provided a molecular key to enable more rapid diagnosis and target for novel therapeutics in the myeloproliferative neoplasms. ...